Neoadjuvant Immunotherapy Proves Superior to Targeted Therapy in Stage III Melanoma
In a groundbreaking study at the European Society of Medical Oncology (ESMO) Congress 2024, researchers revealed that neoadjuvant immunotherapy significantly enhances outcomes for patients with stage III melanoma
Significant Findings
The standard approach for resectable stage IIIB or greater melanoma has evolved with new data supporting the effectiveness of neoadjuvant therapy. The latest updates indicate that those achieving a major pathological response (MPR) experience long-lasting benefits.
Study Overview
- Georgina Long, co-medical director at Melanoma Institute Australia, reported these findings.
- The study focused on a pooled analysis of 818 patients with stage IIIB or higher melanoma.
- From this cohort, 610 received neoadjuvant immunotherapy (ICI) therapies.
Key Results
Of the patients studied, 55% achieved an MPR, with the highest rates seen in those treated with ICI therapies. Specifically, patients receiving PD-1 plus CTLA-4 had a 62% MPR rate, indicating a strong correlation between therapy type and outcomes.
Implications for Future Research
These results suggest a shift in treatment paradigms for melanoma, emphasizing the need to explore alternative treatments for patients who do not achieve adequate pathological responses.
The findings advocate for the prioritization of neoadjuvant immunotherapy over targeted therapies, particularly in cases of high-risk melanoma.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.